Keeping Clinical Trials Running During a Pandemic

Oncology

Harnessing Macrophage Biology to Overcome Tumor Immune Evasion

Roy Maute, Ph.D.

Pheast Therapeutics

Pathfinder

Basket vs. Umbrella Clinical Trials: Which Precision Oncology Trial Design Is Better?

Pharma's Almanac

Pathfinder

Adaptive Trials vs. Traditional Randomized Controlled Trials: Which Clinical Trial Design Is Better?

Pharma's Almanac

Basket Trials

Basket Trials and the Future of Rare Cancer Research

David Alvaro, Ph.D.

Pharma's Almanac

Pathfinder

Site-Based vs. Decentralized vs. Hybrid Clinical Trials: Which Model Is Best for Modern Clinical Research?

Pharma's Almanac

Adaptive Trials

Designing for Change: Adaptive Clinical Trials and the Evolving Path to Regulatory Acceptance

Pharma's Almanac

CRO Partnerships

Building Resilient Development Models: How Mid-Size Pharma Can Scale Without Losing Control

Brian Healey

IQVIA

Expedited Pathways

Accelerated Pathways: Are They Delivering on Their Promise?

David Alvaro, Ph.D.

Pharma's Almanac

Clinical Evidence

Rethinking Clinical Evidence Requirements in Rare Diseases

David Alvaro, Ph.D.

Pharma's Almanac

Outsourcing

The Hidden Operational Costs of Multi-Vendor Outsourcing Models

Pharma's Almanac

Clinical Trial Needs

Bridging the Gap: Addressing Unmet Needs in Cardiology, Neuroscience, and Respiratory Trials

Bethany Davis, M.D.

Trialmed